Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Admilparant Formulations in Healthy Participants
NCT06715683Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of admilparant in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Concentration-time From Time Zero to Time Last Qualifiable Concentration and 1 more. Started Dec 2024; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT06715683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715683.